Stratos Wealth Partners LTD. Sells 5,266 Shares of Eli Lilly and Company $LLY

Stratos Wealth Partners LTD. trimmed its position in Eli Lilly and Company (NYSE:LLY) by 16.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,044 shares of the company’s stock after selling 5,266 shares during the period. Stratos Wealth Partners LTD.’s holdings in Eli Lilly and Company were worth $29,064,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in LLY. Brighton Jones LLC boosted its stake in Eli Lilly and Company by 22.0% during the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after purchasing an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC lifted its position in shares of Eli Lilly and Company by 2.8% during the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after buying an additional 40 shares in the last quarter. Schnieders Capital Management LLC. lifted its position in shares of Eli Lilly and Company by 16.7% during the 2nd quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company’s stock worth $6,231,000 after buying an additional 1,141 shares in the last quarter. Flow Traders U.S. LLC bought a new position in shares of Eli Lilly and Company during the 2nd quarter worth approximately $356,000. Finally, Jump Financial LLC bought a new position in shares of Eli Lilly and Company during the 2nd quarter worth approximately $6,680,000. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $930.08 on Wednesday. The company has a debt-to-equity ratio of 1.54, a current ratio of 1.58 and a quick ratio of 1.19. The business has a fifty day simple moving average of $988.75 and a two-hundred day simple moving average of $973.25. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,133.95. The company has a market capitalization of $878.76 billion, a P/E ratio of 40.53, a P/E/G ratio of 1.09 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, beating analysts’ consensus estimates of $7.48 by $0.06. The firm had revenue of $19.29 billion for the quarter, compared to analysts’ expectations of $17.85 billion. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The business’s revenue for the quarter was up 42.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $5.32 EPS. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Weiss Ratings reissued a “buy (b)” rating on shares of Eli Lilly and Company in a research report on Friday, March 27th. Wells Fargo & Company lifted their target price on shares of Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. Jefferies Financial Group set a $1,300.00 target price on shares of Eli Lilly and Company and gave the stock a “buy” rating in a research report on Friday, March 13th. JPMorgan Chase & Co. lifted their target price on shares of Eli Lilly and Company from $1,150.00 to $1,300.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. Finally, Rothschild & Co Redburn lifted their target price on shares of Eli Lilly and Company from $775.00 to $830.00 and gave the stock a “neutral” rating in a research report on Monday, January 26th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,222.22.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: FDA approval of Foundayo creates a new high‑value product opportunity that could add billions to sales and validate Lilly’s oral GLP‑1 strategy. Great News for Eli Lilly Stock Investors!
• Positive Sentiment: CEO Dave Ricks says Lilly is ready to scale production of Foundayo, reducing execution risk and supporting faster commercialization. Eli Lilly CEO Says Company Ready to Scale Production
• Positive Sentiment: Lilly will manufacture the GLP‑1 at a new Houston facility, supporting supply and limiting bottlenecks as demand ramps. Lilly’s $6.5B Houston plant will make its new FDA-approved GLP-1
• Positive Sentiment: Brokerage reaction includes modest price‑target increases and renewed analyst attention, reflecting confidence in Foundayo’s sales potential despite valuation questions. Price Target Raised Following FDA Approval
• Neutral Sentiment: Lilly amended its collaboration with AC Immune to advance next‑generation Tau aggregation inhibitors with IND‑enabling studies planned in 2026 — diversification into neurodegeneration could be material longer term but won’t move near‑term revenue. Eli Lilly Extends AC Immune Tau Pact
• Negative Sentiment: Pricing pressure: Novo Nordisk launched a lower‑priced Wegovy HD at about a 40% lower cash price than Lilly’s offering, raising concerns that price competition could blunt Foundayo’s revenue and margins. Novo Nordisk Unveils $399 Wegovy HD
• Negative Sentiment: Market commentary flags a broader GLP‑1 price war and side‑effect/competition concerns that have driven short‑term profit‑taking and tempered the stock’s post‑approval rally. Price War Dampens Lilly Surge After Oral GLP-1 Wins FDA Nod

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.